PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10377215" target="_blank" >RIV/00216208:11140/18:10377215 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/18:10377215
Result on the web
<a href="https://doi.org/10.1080/2162402X.2018.1435226" target="_blank" >https://doi.org/10.1080/2162402X.2018.1435226</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2018.1435226" target="_blank" >10.1080/2162402X.2018.1435226</a>
Alternative languages
Result language
angličtina
Original language name
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Original language description
Background. The outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) remains poor. The programmed cell-death-protein-1 (PD-1), a co-inhibitory receptor primarily expressed by T-cells, represents a potential new therapeutic target. PD-1, PD-1 ligand 1 (PD-L1), and PD-L2 expression have all been described as prognostic factors in a variety of cancers. Their expression patterns in AEG, however, are poorly understood. We analyzed PD-L1, PD-L2 and PD-1 expression by tumor-infiltrating lymphocytes (TILs) and cancer-cells in tumor-biospecimens in AEG-patients. Methods. 168 patients who underwent esophagectomy because of AEG between 1992-2011 were included in this study. PD-L1, PD-L2 and PD-1 expression were evaluated by immunohistochemistry and correlated with various clinicopathological parameters, disease-free survival (DFS) and long-term overall survival (OS). Results. PD-L1 expression by cancer-cells (cancer-cell-PD-L1(+)) was found in 43.5% of patients whereas PD-L1 expression by TILs (TILs-PD-L1(+)) was observed in 69%. PD-L2 expression by cancer-cells and TILs was only found in 3.5% and 1.8%, respectively. Additionally, 77.4% of tumors contained PD-1(+)-cancer-cells and 81% PD-1(+)-TILs. Patients with increased expression of PD-1 by cancer-cells and TILs showed significantly reduced OS and DFS, as determined by univariate, but not multivariate analysis. Expression of PD-L1 by cancer-cells was found to be an independent predictor for improved DFS (p = 0.038) and OS (p = 0.042) in multivariate analysis. Conclusions. Cancer cells and TILs displayed PD-L1 expression in around 50% and PD-1 expression in around 80% of tumor-biospecimens obtained from AEG patients. Expression of PD-L1 is an independent predictor of favorable outcome in AEG, whereas PD-1 expression is associated with worse outcome and advanced tumor stage.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
OncoImmunology [online]
ISSN
2162-402X
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
—
UT code for WoS article
000432214900025
EID of the result in the Scopus database
2-s2.0-85043700835